MedWell Ai, Inc. (OTCQB: MWAI) announced on August 18, 2025 that it has retained BrighterMD to develop TeleMD.Ai, a nationwide telemedicine platform scheduled to launch in October 2025. TeleMD.Ai is built to scale across employers and consumers, and it combines subscription economics, enterprise-friendly integrations, AI-enhanced care, biometric monitoring, and deep pharmacy and lab integrations into a single benefits-ready product.
The revenue case is clear. TeleMD. Ai’s subscription model, which provides no copays for telehealth visits, unlimited visits, and predictable monthly fees, enables recurring revenue with straightforward ARR visibility. Enterprise distribution through API or EDI onboarding and reseller channels embeds the service into benefits administration, which raises customer lifetime value by lowering opt-out and churn. For employers, the appeal is simple: forecastable per-employee costs and a path to reduce ER and onsite utilization through timely access to primary care.
Where TeleMD.Ai excels is the combination of technology and clinical flow. The LifeVitals app, FDA registered and reporting 95 percent accuracy on key vitals using a smartphone camera, delivers remote monitoring without extra hardware. Planned AI agents will analyze wearable and patient-reported data to automate triage, deliver personalized coaching, and trigger early interventions. Those capabilities shift the platform from reactive visits to continuous, preventive care, which is how long-term cost savings are realized.
Clinical integration is another strength. TeleMD.Ai connects to a 70,000-plus pharmacy network, offers zero-dollar pickup on a targeted list of acute medications, and delivers home delivery for many chronic meds. Savings of up to 80 percent on prescriptions and lab work strengthen the member value proposition and create tangible, trackable cost reductions for employers and employees alike. Teletherapy and 24/7 behavioral health access with zero-dollar consults broaden the benefit and drive utilization and retention.
Distribution and execution advantages matter in digital health, and this project brings experienced partners to market. BrighterMD’s team has implemented solutions for major channels, including work for Trump Mobile and payroll/integration partners. That experience reduces implementation friction, shortens time to initial enterprise wins, and improves the odds of early scale through reseller and payroll channels.
Market reach is expanded by bilingual clinical services and optional add-ons like wellness management and TelePetCare, which increase appeal to diverse workforces and boost enrollment opportunities for part-time and uninsured populations. Those features support higher covered lives per contract and make the platform a flexible addition to existing benefits stacks.
Key signals investors should monitor after launch include enterprise contracts through reseller or payroll partners, measured pharmacy and lab savings for early clients, enrollment and utilization metrics, retention and churn rates for employer-sponsored members, and evidence that LifeVitals and AI interventions increase engagement and reduce downstream spend.
TeleMD.Ai positions MWAI to capture both predictable enterprise revenue and scalable retail subscription growth. If initial enterprise onboarding shows measurable cost savings and the technology features drive higher engagement, TeleMD.Ai could change how employers manage primary care access and benefits economics.